Utilising a Cohort Study of Hepatitis B Virus (HBV) Vaccine-Mediated Immunity in South African Children to Model Infection Dynamics: Can We Meet Global Targets for Elimination by 2030?
暂无分享,去创建一个
P. Klenerman | Sunetra Gupta | M. Ansari | K. Jeffery | J. Lourenço | P. Matthews | P. Goulder | E. Adland | L. Hattingh | A. McNaughton | S. Wareing | Pieter Jooste | S. Daniels | Anriette van Zyl | Connie S Akiror
[1] Susan A. Doyle,et al. The effect of timing of influenza vaccination and sample collection on antibody titers and responses in the aged. , 2017, Vaccine.
[2] T. Ndung’u,et al. PARV4 prevalence, phylogeny, immunology and coinfection with HIV, HBV and HCV in a multicentre African cohort , 2017, Wellcome open research.
[3] L. Piroth,et al. Hepatitis B virus vaccination in HIV-infected people: A review , 2017, Human vaccines & immunotherapeutics.
[4] J. Beghin,et al. Effectiveness of the South African expanded program of immunization against hepatitis B in children infected with human immunodeficiency virus‐1 living in a resource‐limited setting of Kwazulu‐Natal , 2017, Journal of medical virology.
[5] K. Jeffery,et al. Screening, characterisation and prevention of Hepatitis B virus (HBV) co-infection in HIV-positive children in South Africa , 2016, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[6] T. Hallett,et al. Requirements for global elimination of hepatitis B: a modelling study. , 2016, The Lancet. Infectious diseases.
[7] Gérard Krause,et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013 , 2015, The Lancet.
[8] M. Cotton,et al. Hepatitis B virus infection in HIV-exposed infants in the Western Cape, South Africa. , 2015, Vaccine.
[9] T. Ndung’u,et al. Prevalence and Characteristics of Hepatitis B Virus (HBV) Coinfection among HIV-Positive Women in South Africa and Botswana , 2015, PloS one.
[10] B. Walker,et al. Sex Differences in Antiretroviral Therapy Initiation in Pediatric HIV Infection , 2015, PloS one.
[11] N. Crowcroft,et al. How and why researchers use the number needed to vaccinate to inform decision making--a systematic review. , 2015, Vaccine.
[12] D. Corley,et al. Vertical Transmission of Hepatitis B Virus , 2014, Annals of Internal Medicine.
[13] P. Klenerman,et al. Epidemiology and impact of HIV coinfection with hepatitis B and hepatitis C viruses in Sub-Saharan Africa. , 2014, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[14] D. Reynders,et al. Investigating hepatitis B immunity in patients presenting to a paediatric haematology and oncology unit in South Africa. , 2014, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.
[15] G. Borgia,et al. Vertical transmission of hepatitis B virus: challenges and solutions , 2014, International journal of women's health.
[16] R. Burnett,et al. Evidence for a change in the epidemiology of hepatitis B virus infection after nearly two decades of universal hepatitis B vaccination in South Africa , 2014, Journal of medical virology.
[17] H. Whittle,et al. Efficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia Hepatitis Intervention Study (1986–90) and in the nationwide immunisation program , 2014, BMC Infectious Diseases.
[18] R. Tedder,et al. The epidemiology of hepatitis B virus infection in HIV-infected and HIV-uninfected pregnant women in the Western Cape, South Africa☆ , 2013, Vaccine.
[19] G. Mieli-Vergani,et al. Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines: consensus of an expert panel on behalf of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. , 2013, Journal of hepatology.
[20] S. Healy,et al. HIV/HBV coinfection in children and antiviral therapy , 2013, Expert review of anti-infective therapy.
[21] C. Klingler,et al. Cost-effectiveness analysis of an additional birth dose of Hepatitis B vaccine to prevent perinatal transmission in a medical setting in Mozambique. , 2012, Vaccine.
[22] R. Burnett,et al. An update after 16 years of hepatitis B vaccination in South Africa. , 2012, Vaccine.
[23] Desmond J. Martin,et al. HBV/HIV co-infection: the dynamics of HBV in South African patients with AIDS. , 2012, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.
[24] L. Aurpibul,et al. Prevalence of protective level of hepatitis B antibody 3 years after revaccination in HIV-infected children on antiretroviral therapy. , 2011, Vaccine.
[25] T. Bärnighausen,et al. Levels of childhood vaccination coverage and the impact of maternal HIV status on child vaccination status in rural KwaZulu-Natal, South Africa* , 2009, Tropical medicine & international health : TM & IH.
[26] W. Borkowsky,et al. Immunogenicity and immunologic memory after hepatitis B virus booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. , 2009, The Journal of infectious diseases.
[27] Ryan T Novak,et al. Persistence of Protection Against Hepatitis B Virus Infection Among Adolescents Vaccinated With Recombinant Hepatitis B Vaccine Beginning at Birth: A 15-Year Follow-Up Study , 2008, The Pediatric infectious disease journal.
[28] R. Harrington,et al. Independent clinical predictors of impaired response to hepatitis B vaccination in HIV-infected persons , 2008, International journal of STD & AIDS.
[29] A. De Luca,et al. Serological response to hepatitis B virus vaccine in HIV‐infected children in Tanzania , 2008, HIV medicine.
[30] L. Aurpibul,et al. Antibody response to hepatitis B re-vaccination in HIV-infected children with immune recovery on highly active antiretroviral therapy. , 2007, Vaccine.
[31] J. Brok,et al. Hepatitis B immunisation for newborn infants of hepatitis B surface antigen‐positive mothers , 2006 .
[32] T. Puthanakit,et al. Prevalence of protective antibody against hepatitis B virus in HIV-infected children with immune recovery after highly active antiretroviral therapy. , 2006, Vaccine.
[33] G. Leroux-Roels,et al. Hepatitis B virus and human immunodeficiency virus co‐infection in sub‐Saharan Africa: a call for further investigation , 2005, Liver international : official journal of the International Association for the Study of the Liver.
[34] H. Kelly,et al. The number needed to vaccinate (NNV) and population extensions of the NNV: comparison of influenza and pneumococcal vaccine programmes for people aged 65 years and over. , 2004, Vaccine.
[35] Graham F. Medley,et al. Hepatitis-B virus endemicity: heterogeneity, catastrophic dynamics and control , 2001, Nature Medicine.
[36] P. van Damme,et al. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. , 2000, Vaccine.
[37] H. Whittle,et al. What level of hepatitis B antibody is protective? , 1999, The Journal of infectious diseases.
[38] P. van Damme,et al. Integration of hepatitis B vaccination into national immunisation programmes , 1997, BMJ.
[39] B. McMahon,et al. Frequency of adverse reactions to hepatitis B vaccine in 43,618 persons. , 1992, The American journal of medicine.
[40] S. Hadler,et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. , 1986, The New England journal of medicine.
[41] A. Dibisceglie,et al. Prevalence of hepatitis B virus infection among black children in Soweto. , 1986, British medical journal.
[42] R. Mikolajczyk,et al. Time trends of chronic HBV infection over prior decades - A global analysis. , 2017, Journal of hepatology.
[43] A. Floreani,et al. Long-term persistence of anti-HBs after vaccination against HBV: an 18 year experience in health care workers. , 2004, Vaccine.